羧基麦芽糖铁对慢性肾脏病与妊娠患者骨及血液学标志物的对照研究
结果显示各组完整FGF23在次日达峰、血磷在第7天降至低谷并随后恢复,基线血磷、FEPi和按体重调整的FCM剂量是低磷血症的独立预测因素。
要点
- 静脉FCM后完整FGF23第2天达峰,血磷低谷与FEPi峰值均在第7天。
- 妊娠组血磷第21天恢复,其他组第42天恢复。
- 基线血磷、FEPi及体重调整剂量可预测低磷血症风险。
核心结论
- 静脉FCM后骨与血液学标志物变化在不同患者组间存在差异。
- 对基线血磷较低者,限制剂量并在给药7天后检测血磷可能减轻临床显著的低磷血症。
研究设计与样本
- 输注1 g静脉FCM,基线至输注后42天随访骨与血液学标志物。
主要发现
- 完整FGF23在各组均于第2天达峰,C端FGF23组间变化明显不同。
- 血磷低谷与FEPi峰值均出现在第7天,妊娠组第21天、其他组第42天恢复。
- 血浆铁调素第2天达峰,血清铁蛋白与转铁蛋白饱和度均于第7天达峰。
- 低血磷谷值的独立预测因素包括基线血磷、FEPi和体重调整的FCM剂量。
临床怎么用
- 对基线血磷偏低的患者,可考虑限制FCM剂量并于给药7天后复查血磷以识别低磷血症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous (IV) iron can modulate fibroblast growth factor 23 (FGF23) concentrations and cause transient but significant hypophosphataemia. However, it is unknown what other markers might be involved, especially in different patient groups. This study aimed to determine changes in bone and haematinic biomarkers following IV ferric carboxymaltose (FCM) and to identify risk factors for hypophosphataemia in pregnant subjects and those with chronic kidney disease (CKD). METHODS: Changes in bone [serum FGF23, fractional excretion of phosphate urinary fractional excretion of phosphate (FEPi), serum phosphate and serum vitamin D derivatives] and haematinic [plasma hepcidin, serum ferritin and transferrin saturation (TSAT)] biomarkers after 1 g of IV FCM were followed in iron-deficient pregnant and CKD patients and compared with controls (estimated glomerular filtration rate > 60 mL/min/1.73 m2). Data were collected at baseline and up to 42 days after infusion. Risk factors for post-FCM hypophosphataemia were also assessed. RESULTS: Sixty-five subjects completed the study (control, n = 20; pregnant, n = 20; CKD, n = 25). A uniform but variable increase across groups was seen in intact FGF23 (peak Day 2), whereas c-terminal FGF23 varied markedly. Trough serum phosphate timed with the peak FEPi at Day 7, recovering by Day 21 in the pregnant group and Day 42 in other groups. Independent predictors of a low phosphate nadir included baseline phosphate, FEPi and weight-adjusted FCM dose. All groups showed an early and marked increase in plasma hepcidin (peak Day 2), serum ferritin and TSAT (peak Day 7 for both). CONCLUSIONS: Changes in bone and haematinic biomarkers differ between patient groups following IV FCM. For patients with lower serum phosphate concentrations, limiting the dose and measuring levels 7 days after administration may mitigate clinically significant hypophosphataemia.
引用
- Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018. PMID: 29165637. doi:10.1093/ndt/gfx310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。